These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 537886)

  • 21. [The antimicrobial activity of amikacin in comparison with three other aminoglycoside-antibiotics (author's transl)].
    Jotzoff M
    Med Klin; 1978 Jun; 73(24):914-7. PubMed ID: 661734
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in resistance to aminoglycoside antibiotics of different bacterial strains isolated during the period 1978 to 1983. Netilmicin as alternative therapy.
    Bovelacci A; Montini G; Ramacciotti PG
    Chemioterapia; 1985 Dec; 4(6):439-44. PubMed ID: 3830413
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Sensitivity of gram-negative germs to Amikacin].
    Redjeb SB; Ennaifer M; Bissardon O; Ben Salah N; Boujnah A
    Tunis Med; 1979; 57(2-3):103-6. PubMed ID: 553336
    [No Abstract]   [Full Text] [Related]  

  • 24. In vitro interaction between cefotetan and aminoglycosides on Staphylococcus aureus and coagulase negative staphylococci, both methicillin-susceptible and -resistant.
    Stefani S; Debbia E; Schito GC; Nicoletti G
    Chemioterapia; 1988 Jun; 7(3):151-5. PubMed ID: 3168069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The antibacterial activity of amikacin in comparison with four other aminoglycoside antibiotics (proceedings)].
    Schassan HH
    Zentralbl Bakteriol Orig A; 1976 Aug; 235(1-3):320-8. PubMed ID: 983520
    [No Abstract]   [Full Text] [Related]  

  • 26. In vitro activity of isepamicin and other aminoglycosides against clinical isolates of Gram-negative bacteria causing nosocomial bloodstream infections.
    Tsai TY; Chang SC; Hsueh PR; Feng NH; Wang JT
    J Microbiol Immunol Infect; 2007 Dec; 40(6):481-6. PubMed ID: 18087627
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Amikacin in the treatment of Gram negative bacilli septicemias].
    Cartier F; Dien G; Cormier M; Hoel JC; Guivarch G
    Nouv Presse Med; 1979 Oct; 8(42):3510-12. PubMed ID: 537908
    [No Abstract]   [Full Text] [Related]  

  • 28. Synergism involving penicillinase-resistant penicillin.
    Levy J; Klastersky J
    Arch Intern Med; 1980 Nov; 140(11):1555-6. PubMed ID: 7436660
    [No Abstract]   [Full Text] [Related]  

  • 29. [Comparison of the bactericidal activity of three aminosides: gentamicin, tobramycin and amikacin].
    Juvin ME; Drugeon HB; Caillon J; Pirault JL
    Pathol Biol (Paris); 1987 May; 35(5):461-5. PubMed ID: 3302848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Comparative study and time changes in the resistance to gentamycin, tobramycin, sisomicin and amikacin of Gram-negative nosocomial bacterial strains isolated from the urinary tract, in relation to the annual use of the aminoglycosides tested].
    Alegente G; Marchi B; Pieri I; Saturni A; Progenie G; Rubino M
    Quad Sclavo Diagn; 1983 Sep; 19(3):343-8. PubMed ID: 6677931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Patterns of resistance of Staph aureus and gram-negative bacteria to aminoglycosides and cephalosporins].
    Ruczkowska J; Dolna I
    Wiad Lek; 1989 May; 42(9):579-83. PubMed ID: 2629327
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Nosocomial catheter-related sepsis secondary to central venous catheters].
    Wu H; Wu Z; Jin D; Xu J
    Zhonghua Wai Ke Za Zhi; 1999 Nov; 37(11):651-3. PubMed ID: 11829916
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Current status of aminoglycoside resistance in hospital Enterobacteriaceae].
    Ronco E; Migueres ML; Vacheron F; Guenounou M
    Pathol Biol (Paris); 1988 May; 36(5):430-4. PubMed ID: 3043339
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and microbiologic consequences of amikacin use during a 42-month period.
    Berk SL; Alvarez S; Ortega G; Verghese A; Holtsclaw-Berk SA
    Arch Intern Med; 1986 Mar; 146(3):538-41. PubMed ID: 3954526
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro susceptibility of gram negative bacteria to amikacin and its comparison with three other aminoglycoside antibiotics.
    Daniel J; Thomas M; Shanmugam J
    Indian J Pathol Microbiol; 1985 Apr; 28(2):115-9. PubMed ID: 3835114
    [No Abstract]   [Full Text] [Related]  

  • 36. In vitro activity of isepamicin (Sch 21420), a new aminoglycoside.
    Qadri SM; Ueno Y; Tullo D; Saldin H
    Chemotherapy; 1995; 41(1):14-7. PubMed ID: 7875017
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Resistance to amikacin of gentamicin-resistant Staphylococcus aureus].
    Yourassowsky E; Van der Linden MP; Lismont MJ; Debusschere P; Crokaert F
    Acta Clin Belg; 1980; 35(6):384-5. PubMed ID: 7331667
    [No Abstract]   [Full Text] [Related]  

  • 38. Pharmacological evaluation of amikacin in neonates.
    Howard JB; McCracken GH
    Antimicrob Agents Chemother; 1975 Jul; 8(1):86-90. PubMed ID: 1164009
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cefoxitin, amikacin, and Pseudomonas aeruginosa resistance.
    Martinez-Forde JM; Garcia-Caballero J; Aguado-Matorras A
    Lancet; 1982 Sep; 2(8300):719-20. PubMed ID: 6126652
    [No Abstract]   [Full Text] [Related]  

  • 40. Cefotaxime and amikacin: results of in vitro and in vivo studies against Gram-negative bacteria and Staphylococcus aureus. EORTC International Antimicrobial Therapy Project Group.
    Klastersky J; Gaya H; Zinner SH; Bernard C; Ryff JC
    J Antimicrob Chemother; 1980 Sep; 6 Suppl A():55-61. PubMed ID: 6252180
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.